NasdaqCM - Nasdaq Real Time Price USD

Tharimmune, Inc. (THAR)

1.1697

-0.0303

(-2.53%)

At close: April 22 at 4:00:00 PM EDT

1.1100

-0.06

(-5.10%)

After hours: April 22 at 7:01:28 PM EDT

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas ...

ACCESS Newswire 7 days ago

THAR
-2.53%
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline ...

ACCESS Newswire 15 days ago

THAR
-2.53%
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway -Company leveraging existing human pharmacokinetic data with TH104 -Advancing CMC plan to meet requirements of a New Drug Application BRIDGEWATER, NJ / ACCESS ...

ACCESS Newswire 22 days ago

THAR
-2.53%
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...

ACCESS Newswire 29 days ago

THAR
-2.53%
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline ...

ACCESS Newswire last month

THAR
-2.53%
Tharimmune to Present at the Microcap Conference 2025

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January ...

ACCESS Newswire 2 months ago

THAR
-2.53%
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients ...

ACCESS Newswire 4 months ago

THAR
-2.53%
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross ...

ACCESS Newswire 4 months ago

THAR
-2.53%
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 /DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a ...

ACCESS Newswire 4 months ago

NNVC

UBI.AX

UBIO.AX
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025 BRIDGEWATER, ...

ACCESS Newswire 5 months ago

THAR
-2.53%
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

ACCESS Newswire 5 months ago

THAR
-2.53%
Tharimmune Announces Upcoming Conference Presentations

BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that ...

ACCESS Newswire 5 months ago

THAR
-2.53%
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive ...

ACCESS Newswire 5 months ago

THAR
-2.53%
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profile TH104 was well tolerated with no unexpected treatment-emergent adverse events, supporting ...

ACCESS Newswire 5 months ago

THAR
-2.53%
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

- Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - Merger anticipated to close in 1Q25 BRIDGEWATER, ...

ACCESS Newswire 6 months ago

THAR
-2.53%
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, ...

ACCESS Newswire 7 months ago

THAR
-2.53%
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced ...

ACCESS Newswire 8 months ago

THAR
-2.53%
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment ...

ACCESS Newswire 9 months ago

THAR
-2.53%
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

BRIDGEWATER, NJ / ACCESSWIRE / July 16, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announces the launch ...

ACCESS Newswire 9 months ago

THAR
-2.53%
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Pharmacokinetic profile of oral transmucosal delivery of TH104 was comparable to intravenous delivery of reference drug Positive safety/tolerability achieved with TH104 reporting a mild side-effect profile Planning for Phase 2 trial for moderate-to-severe ...

ACCESS Newswire 10 months ago

THAR
-2.53%

Performance Overview

Return	THAR	S&P 500 (^GSPC)
YTD	-42.38%	-10.10%
1-Year	-78.92%	+5.53%
3-Year	-99.76%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tharimmune, Inc. (THAR)

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Performance Overview